Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MUC4
REST API REST API
Homo sapiens
MUC4 is differentially expressed in 229 experiments: 138 organism parts: trachea, prostate, ... (136 more);, 123 disease states: normal, chronic myelogenous leukemia, ... (121 more);, 66 cell types 283 cell lines 24 compound treatments and 70 other conditions.
Orthologs MUC4 (Danio rerio)   F1M7W8_RAT (Rattus norvegicus)   MUC4 (Gallus gallus)   MUC1 (Saccharomyces cerevisiae)   CG4835 (Drosophila melanogaster)   Muc4 (Mus musculus)   ENSCING00000016968 (Ciona intestinalis)   muc4 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term protein binding, cell-matrix adhesion
InterPro Term Nidogen_extracell_dom, AMOP, EGF_3, EGF-like, VWF_type-D
UniProt Accession Q99102, O75456, E7ENC5, E7EQT2, E7EQG8, E7ERK0, E7ETT5, E7EUL9, E7EWN1, E7EW47, E9PDY6
Search EB-eye ENSG00000145113
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-7224, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (32 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
MDA468
2
E-MTAB-62, E-MEXP-440
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
GM15510
2
E-GEOD-19466, E-GEOD-22639
SW480
2
E-MEXP-1014, E-GEOD-18005
K562
1
2
E-GEOD-96, E-GEOD-24147, E-MTAB-37
277 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, E-GEOD-20677, ... (36 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
naive B cell
1
E-TABM-702
type I helper T cell
1
E-GEOD-3982
monocyte
1
E-GEOD-11755
induced pluripotent stem cell
1
E-GEOD-18265
primary fibroblast
1
E-MEXP-66
60 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (51 experiments)

Factor Value U/D Experiments
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
chronic myelogenous leukemia K562
2
E-AFMX-5, E-TABM-145
Daudi Burkitt's lymphoma
1
E-AFMX-5
gastric carcinoma
1
E-GEOD-15460
117 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-697, E-GEOD-5824, E-GEOD-5099, ... (16 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5824, E-GEOD-412, E-GEOD-697, E-MEXP-1389, E-GEOD-20719, ... (6 experiments)
hydrogen peroxide
1
E-GEOD-5339
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
unknown
1
E-GEOD-7307
1mM GDC-0941
1
1
E-GEOD-20719
eicosapentaenoic acid
1
E-MEXP-1389
18 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
29 years
1
1
E-GEOD-4922
40
2
1
E-GEOD-21653
43
2
1
E-GEOD-21653
29
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-MEXP-480, E-TABM-147, E-GEOD-21138, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-MTAB-108, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-TABM-147

Tumor size
studied in E-GEOD-3494

Processing time: 0.271 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM